Anti-FGF2 antibody [EPR20145-227],Abcam,AB215373
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
WB, IP
Platform ID
BAB739568039
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed : 8663044). Also acts as an integrin ligand which is required for FGF2 signaling (PubMed : 28302677). Binds to integrin ITGAV : ITGB3 (PubMed : 28302677). Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration (PubMed : 28302677, PubMed : 8663044). Functions as a potent mitogen in vitro (PubMed : 1721615, PubMed : 3732516, PubMed : 3964259). Can induce angiogenesis (PubMed : 23469107, PubMed : 28302677). Mediates phosphorylation of ERK1/2 and thereby promotes retinal lens fiber differentiation (PubMed : 29501879). See full target information FGF2
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.